scholarly journals Bronchial ethanol injection therapy for airway obstruction in lung cancer patients

2021 ◽  
Vol 9 (9) ◽  
Author(s):  
Fukuko Okabe ◽  
Yukihiro Yano ◽  
Tomoki Kuge ◽  
Takeshi Uenami ◽  
Masaki Kanazu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Airway Obstruction ◽  
Cancer Patients ◽  
Injection Therapy ◽  
Ethanol Injection ◽  
Lung Cancer Patients ◽  
Ethanol Injection Therapy

scholarly journals The Efficacy of External Beam Radiotherapy for Airway Obstruction in Lung Cancer Patients

2014 ◽  
Vol 47 (2) ◽  
pp. 189-196 ◽  
Author(s):  
Jeong Won Lee ◽  
Jong Hoon Lee ◽  
Hoon-Kyo Kim ◽  
Byoung Yong Shim ◽  
Ho Jung An ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Airway Obstruction ◽  
Cancer Patients ◽  
External Beam Radiotherapy ◽  
External Beam ◽  
Lung Cancer Patients

scholarly journals Palliative external beam radiotherapy for lung cancer patients with malignant airway obstruction

2020 ◽  
Author(s):  
Hoon Sik Choi ◽  
Bae Kwon Jeong ◽  
Hojin Jeong ◽  
In Bong Ha ◽  
Ki Mun Kang
Keyword(s):  
Lung Cancer ◽  
Radiation Dose ◽  
Airway Obstruction ◽  
Cancer Patients ◽  
Tumor Response ◽  
External Beam Radiotherapy ◽  
Symptom Improvement ◽  
High Dose ◽  
External Beam ◽  
Lung Cancer Patients

Abstract Background Significant proportion of lung cancer patients suffer from malignant airway obstruction (MAO). Palliative external beam radiotherapy (EBRT) is often attempted to control symptoms caused by MAO. In this study, we report the effect of palliative EBRT on lung cancer with MAO and analyze the factors that influence it. Methods This study included 75 patients with MAO in lung cancer who underwent palliative EBRT, between 2009 and 2018 and were analyzed retrospectively. Change of dyspnea, tumor response, and overall survival (OS) were recorded. Univariate and multivariate analyses were done to find the prognostic factors for treatment outcomes. Results The median follow-up duration was 2.5 months, and the median OS was 2.3 months. Out of 75 patients, dyspnea was improved in 46 patients (61.3%), and tumor was partially decreased in 39 patients (52%). The symptom improvement was significantly affected by tumor response and radiation dose. The tumor response was significantly affected by disease status, radiation dose, and time to EBRT.Conclusions Palliative EBRT is an effective and safe treatment option for patients with MAO in lung cancer. Especially, high-dose irradiation and prompt treatment can improve treatment results.

Cutaneous Side Effects in 19 Lung Cancer Patients Treated with Gefitinib (Iressa)

2004 ◽  
Vol 66 (6) ◽  
pp. 602-607 ◽  
Author(s):  
Miho UCHIHIRA ◽  
Takahiro EJIMA ◽  
Takao UCHIHIRA ◽  
Jun ARAKI ◽  
Toshiaki KAMEI
Keyword(s):  
Lung Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Cutaneous Side Effects ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document